1/1
2 files

Contrasting associations between diabetes and cardiovascular mortality rates in low, middle and high-income countries – Cohort study data from 143,567 individuals in 21 countries – The PURE study

figure
posted on 15.10.2020 by Ranjit Mohan Anjana, Viswanathan Mohan, Sumathy Rangarajan, Hertzel C Gerstein, Ulagamadesan Venkatesan, Patrick Sheridan, Gilles R Dagenais, Scott A Lear, Koon Teo, Kubilay Karsidag, Khalid F Alhabib, Khalid Yusoff, Noorhassim Ismail, Prem K Mony, Patricio Lopez-Jaramillo, Jephat Chifamba, Lia M Palileo-Villanueva, Romaina Iqbal, Afzalhussein Yusufali, Iolanthe M Kruger, Annika Rosengren, Ahmad Bahonar, Katarzyna Zatonska, Karen Yeates, Rajeev Gupta, Wei Li, Lihua Hu, M Omar Rahman, Lakshmi PVM, Thomas Iype, Alvaro Avezum, Rafael Diaz, Fernando Lanas, Salim Yusuf
Objectives: We aimed to compare cardiovascular (CV) events, all-cause and CV mortality rates, among adults with and without diabetes in countries with differing levels of income.

Research design and methods: Prospective Urban Rural Epidemiological (PURE) enrolled 143,567 adults aged 35 to 70 years from 4 high income countries (HIC), 12 middle income countries (MIC) and 5 low income countries (LIC). The mean follow-up was 9.0±3.0 years.

Results: Among those with diabetes, CVD rates (LIC 10.3, MIC 9.2, HIC 8.3 per 1000 person years, p<0.001), all-cause mortality (LIC 13.8, MIC 7.2, HIC 4.2 per 1000 person years, p<0.001) and CV mortality (LIC 5.7, MIC 2.2, HIC 1.0 per 1000 person years, p<0.001) were considerably higher in LIC compared to MIC and HIC. Within LIC, mortality was higher in those in the lowest tertile of wealth index (low 14.7%, middle 10.8%, high 6.5%). In contrast to HIC and MIC, the increased CV mortality in those with diabetes in LIC remained unchanged even after adjustment for behavioural risk factors and treatments [Hazards ratio (95% Confidence Interval): 1.89 (1.58 – 2.27) to 1.78 (1.36 – 2.34)].

Conclusions: CVD rates, all-cause and CV mortality were markedly higher among those with diabetes in LIC compared to MIC and HIC with mortality risk remaining unchanged even after adjustment for risk factors and treatments. There is an urgent need to improve access to care to those with diabetes in LIC to reduce the excess mortality rates, particularly among those in the poorer strata of society.

Funding

This work was supported by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Support from Canadian Institutes of Health Research’s Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies [with major contributions from AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GlaxoSmithKline], and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. Dr S Yusuf is supported by the Mary W Burke endowed chair of the Heart and Stroke Foundation of Ontario.

History

Exports

Logo branding

Exports